Equities research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Shares of NASDAQ TTNP opened at $5.66 on Friday. Titan Pharmaceuticals has a 52-week low of $4.24 and a 52-week high of $14.80. The business has a fifty day moving average of $5.93 and a two-hundred day moving average of $6.44.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Investing In Automotive Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- Technology Stocks Explained: Here’s What to Know About Tech
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
